Product
FDQ21A-NH
1 clinical trial
2 indications
Indication
InfluenzaIndication
HumanClinical trial
A Phase 1 Randomized, Observer-blind, Dose-escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an mRNA-based Monovalent Influenza Vaccine Candidate in Healthy Younger and Older AdultsStatus: Completed, Estimated PCD: 2024-04-04